Publication: MiR-30a-5p hampers proliferation of lung squamous cell carcinoma through targeting FBXO45
Authors
Zeng, Fanye ; You, Shuqing ; Dai, Xueli
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-424
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Objective. Studies have elaborated the
inhibition of miR-30a-5p on the proliferation of cancer
cells. However, the regulatory mechanism of how miR30a-5p works in lung squamous cell carcinoma (LUSC)
cells is obscure.
Methods. Data of miRNAs/mRNAs in LUSC tissue
(The Cancer Genome Atlas (TCGA)) were accessed. A
differential upstream miRNA (miR-30a-5p) was
obtained by differential analysis. Downstream target
mRNAs were predicted and screened by several
databases. The function pathways of target protein in
cells were determined by gene set enrichment analysis
(GSEA). Abnormal expression levels of FBXO45 and
miR-30a-5p were evaluated in three LUSC cell lines.
The expression levels of FBXO45 mRNA and miR-30a5p were analyzed by qRT-PCR. Western blot method
was employed to assess protein levels of FBXO45,
Cyclin E1, Cdk4 and Cyclin D1. How the two
researched genes interact was testified by dual-luciferase
method. Cell proliferative ability was compared by
CCK-8 and colony formation methods. Moreover, cell
cycle was tested by flow cytometry.
Results. MiR-30a-5p was tested to be noticeably
down-regulated in LUSC cell lines. Up-regulated
FBXO45 in LUSC was targeted by miR-30a-5p.
Overexpressing miR-30a-5p modulated proliferation and
cell cycle in LUSC via inhibiting FBXO45.
Conclusion. MiR-30a-5p hindered FBXO45
expression to repress the proliferation of LUSC.
FBXO45/miR-30a-5p may shed light on future
molecular treatment of LUSC.
publication.page.subject
Citation
Histology and Histopathology Vol. 37, nº5 (2022)
item.page.embargo
Ir a EstadÃsticas
Este Ãtem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/